Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Revises Guidance To Reflect New Warning For Chantix Label

This article was originally published in The Pink Sheet Daily

Executive Summary

World's largest drug maker posts 1 percent increase in worldwide pharmaceutical sales over 2006; says new drugs Chantix, Lyrica show strong growth.

You may also be interested in...



Publicity May Have Compounded Chantix Psychiatric Reports, Pfizer Implies

Adverse event reports jumped in Q3/Q4 following erratic patient's murder, FDA MedWatch alert and resulting publicity, firm says.

Publicity May Have Compounded Chantix Psychiatric Reports, Pfizer Implies

Adverse event reports jumped in Q3/Q4 following erratic patient's murder, FDA MedWatch alert and resulting publicity, firm says.

Pfizer Earnings Fall 18% On Loss Of Zyrtec, Norvasc

First quarter revenues also are down 5 percent to $12.5 billion, but Lyrica and Chantix see gains.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS066774

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel